Literature DB >> 16637809

Invasive squamous cell carcinoma arising in refractory perianal Bowen's disease in a HIV-positive individual.

Asoka Herat1, Kyoko Shirato, Diona L Damian, Robert Finlayson, Margot Whitfeld.   

Abstract

A 54-year-old HIV-positive homosexual man presented with erythematous and pigmented plaques on background erythema in the perianal region, histologically consistent with Bowen's disease. Perianal Bowen's disease represents high-grade anal intraepithelial neoplasia, which is considered a precursor lesion of invasive anal squamous cell carcinoma. This patient's anal intraepithelial neoplasia was unresponsive to multiple treatment modalities including cryotherapy, serial curettage and cautery, topical 5-fluorouracil and 5-aminolaevulinic acid photodynamic therapy. He progressed to develop a poorly differentiated squamous cell carcinoma of the anus three and a half years after the Bowen's disease was diagnosed. The squamous cell carcinoma was treated with combined chemoradiation. A recurrence of high-grade anal intraepithelial neoplasia was noted 6 months after completion of chemoradiation.

Entities:  

Mesh:

Year:  2006        PMID: 16637809     DOI: 10.1111/j.1440-0960.2006.00246.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  4 in total

Review 1.  Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).

Authors:  Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

2.  Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report.

Authors:  Filip Troicki; Alexandros Pappas; Robert Noone; Albert Denittis
Journal:  J Med Case Rep       Date:  2010-02-24

3.  Management of anal squamous intraepithelial lesions.

Authors:  Carlos E Pineda; Mark L Welton
Journal:  Clin Colon Rectal Surg       Date:  2009-05

4.  Bowen's disease - a review of newer treatment options.

Authors:  Thorsten Neubert; Percy Lehmann
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.